Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;11(1):49-56.
doi: 10.1212/CPJ.0000000000000832.

Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019

Abelardo Araujo  1 , Charles R M Bangham  1 , Jorge Casseb  1 , Eduardo Gotuzzo  1 , Steve Jacobson  1 , Fabiola Martin  1 , Augusto Penalva de Oliveira  1 , Marzia Puccioni-Sohler  1 , Graham P Taylor  1 , Yoshihisa Yamano  1
Affiliations
Review

Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019

Abelardo Araujo et al. Neurol Clin Pract. 2021 Feb.

Abstract

Purpose of review: To provide an evidence-based approach to the use of therapies that are prescribed to improve the natural history of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)-a rare disease.

Recent findings: All 41 articles on the clinical outcome of disease-modifying therapy for HAM/TSP were included in a systematic review by members of the International Retrovirology Association; we report here the consensus assessment and recommendations. The quality of available evidence is low, based for the most part on observational studies, with only 1 double-masked placebo-controlled randomized trial.

Summary: There is evidence to support the use of both high-dose pulsed methyl prednisolone for induction and low-dose (5 mg) oral prednisolone as maintenance therapy for progressive disease. There is no evidence to support the use of antiretroviral therapy. There is insufficient evidence to support the use of interferon-α as a first-line therapy.

PubMed Disclaimer

Figures

Figure
Figure. Flow Diagram Documenting the Disposition of Articles During the Systematic Review
See this image and copyright information in PMC

References

    1. European Centre for Disease Prevention and Control. Geographical Distribution of Areas with a High Prevalence of HTLV-1 Infection. Stockholm, Sweden: ECDC; 2015.
    1. Martin F, Taylor GP, Jacobson S. Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Rev Clin Immunol 2014;10:1531–1546. - PubMed
    1. Tanajura D, Castro N, Oliveira P, et al. Neurological manifestations in human T-cell lymphotropic virus type 1 (HTLV-1)-Infected individuals without HTLV-1-associated myelopathy/tropical spastic paraparesis: a longitudinal cohort study. Clin Infect Dis 2015;61:49–56. - PMC - PubMed
    1. World Health Organisation. WHO diagnostic guidelines of HAM. Weekly Epidemiological Rec 1989;49:382–383.
    1. Sato T, Yagishita N, Tamaki K, et al. Proposal of classification criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis disease activity. Front Microbiol 2018;9:1651. - PMC - PubMed